May 22, 2014
Sanford, Florida, May 22, 2014 – Hill Dermaceuticals, Inc®, a privately held pharmaceutical company with 6 NDAs and that develops and manufactures prescription drugs focusing on Dermatologic diseases, announced that the United States Food and Drug Administration (“FDA”) has granted orphan drug designation to its investigational drug for Fungal Otitis Externa (Otomycosis).
TOLL FREE
1-800-344-5707
1-407-323-1887
FAX
1-407-649-9213
© 2023 Hill Dermaceuticals, Inc. Privacy Policy | Terms and Conditions